313 related articles for article (PubMed ID: 37558542)
1. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy.
Contieri R; Hensley PJ; Tan WS; Grajales V; Bree K; Nogueras-Gonzalez GM; Lee BH; Navai N; Dinney CP; Kamat AM
Eur Urol Oncol; 2023 Dec; 6(6):590-596. PubMed ID: 37558542
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
3. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
[TBL] [Abstract][Full Text] [Related]
4. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes.
Tan WS; Grajales V; Contieri R; Hensley P; Bree K; Msaouel P; Guo CC; Nogueras-Gonzalez GM; Navai N; Dinney CP; Kamat AM
Eur Urol Open Sci; 2023 Jul; 53():16-22. PubMed ID: 37441349
[TBL] [Abstract][Full Text] [Related]
5. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer.
Liu K; Zhao H; Chen X; Nicoletti R; Vasdev N; Chiu PK; Ng CF; Kawada T; Laukhtina E; Mori K; Yanagisawa T; D'Andrea D; von Deimling M; Albisinni S; Krajewski W; Pradere B; Soria F; Moschini M; Enikeev D; Shariat S; Kamat A; Giannarini G; Teoh JY;
Eur Urol Oncol; 2024 Jun; 7(3):438-446. PubMed ID: 37827948
[TBL] [Abstract][Full Text] [Related]
6. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin.
Lobo N; Hensley PJ; Bree KK; Nogueras-Gonzalez GM; Navai N; Dinney CP; Sylvester RJ; Kamat AM
Eur Urol Oncol; 2022 Feb; 5(1):84-91. PubMed ID: 34920986
[TBL] [Abstract][Full Text] [Related]
7. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
[TBL] [Abstract][Full Text] [Related]
8. Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics.
Subiela JD; Krajewski W; González-Padilla DA; Laszkiewicz J; Taborda J; Aumatell J; Sanchez Encinas M; Basile G; Moschini M; Caño-Velasco J; Lopez Perez E; Del Olmo Durán P; Gallioli A; Tukiendorf A; D'Andrea D; Yuen-Chun Teoh J; Serna Céspedes A; Pichler R; Afferi L; Del Giudice F; Gomez Rivas J; Albisinni S; Soria F; Ploussard G; Mertens LS; Rajwa P; Laukhtina E; Pradere B; Tully K; Guerrero-Ramos F; Rodríguez-Faba Ó; Alvarez-Maestro M; Dominguez-Escrig JL; Szydełko T; Gomez Dos Santos V; Jiménez Cidre MÁ; Burgos Revilla FJ;
Eur Urol Oncol; 2024 Feb; ():. PubMed ID: 38355375
[TBL] [Abstract][Full Text] [Related]
9. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
10. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
Black PC; Tangen CM; Singh P; McConkey DJ; Lucia MS; Lowrance WT; Koshkin VS; Stratton KL; Bivalacqua TJ; Kassouf W; Porten SP; Bangs R; Plets M; Thompson IM; Lerner SP
Eur Urol; 2023 Dec; 84(6):536-544. PubMed ID: 37596191
[TBL] [Abstract][Full Text] [Related]
12. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
[TBL] [Abstract][Full Text] [Related]
13. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
14. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
[TBL] [Abstract][Full Text] [Related]
15. Intravesical Therapy Compared to Radical Cystectomy Among Patients With Non-Muscle Invasive Bladder Cancer Requiring Additional Treatment After Induction BCG.
Anderson CB; Chen L; Chang SS; McKiernan JM; Wright J
Clin Genitourin Cancer; 2022 Dec; 20(6):595-603. PubMed ID: 35948482
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
17. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
[TBL] [Abstract][Full Text] [Related]
18. Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
Murakami Y; Matsumoto K; Miyake M; Amano N; Shimura S; Nishimura N; Iida K; Matsushita Y; Abe T; Yamada T; Uemura M; Matsui Y; Taoka R; Kojima T; Kobayashi T; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K; Iwamura M
Int J Urol; 2022 Oct; 29(10):1195-1203. PubMed ID: 35858755
[TBL] [Abstract][Full Text] [Related]
19. Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guérin.
Contieri R; Grajales V; Tan WS; Martini A; Sood A; Hensley P; Bree K; Lobo N; Nogueras-Gonzalez GM; Guo CC; Navai N; Dinney CP; Kamat AM
BJU Int; 2024 Jan; 133(1):63-70. PubMed ID: 37442564
[TBL] [Abstract][Full Text] [Related]
20. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
